Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | (Q2)Dec 31, 2022 | (Q1)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 24.58%19.01B | 40.42%5.75B | 25.30%4.73B | 18.97%4.42B | 11.86%4.11B | 27.29%15.26B | 18.55%4.09B | 24.24%3.78B | 28.74%3.72B | 40.80%3.67B |
Cost of revenue | 27.87%12.07B | 49.61%3.63B | 31.11%3.03B | 19.27%2.83B | 10.79%2.58B | 22.28%9.44B | 9.43%2.43B | 20.02%2.31B | 28.27%2.37B | 34.85%2.33B |
Gross profit | 19.26%6.94B | 27.06%2.12B | 16.18%1.71B | 18.44%1.59B | 13.73%1.52B | 36.35%5.82B | 34.88%1.67B | 31.52%1.47B | 29.60%1.34B | 52.53%1.34B |
Operating expense | 16.01%6.64B | 19.48%1.93B | 12.46%1.56B | 11.18%1.48B | 20.11%1.68B | 24.80%5.73B | 21.06%1.61B | 22.03%1.39B | 23.56%1.33B | 33.85%1.4B |
Operating profit | 215.66%298.76M | 249.15%192.17M | 78.32%148.07M | 699.03%113.18M | -168.54%-154.66M | 129.64%94.65M | 157.45%55.04M | 540.57%83.04M | 136.20%14.17M | 65.22%-57.59M |
Net non-operating interest income (expenses) | -43.68%-21.36M | -44.02%-6.09M | -37.71%-5.61M | -45.10%-5.27M | -49.74%-4.39M | -113.93%-14.87M | -71.53%-4.23M | -109.84%-4.07M | -142.81%-3.63M | -180.13%-2.93M |
Non-operating interest expense | 43.68%21.36M | 44.02%6.09M | 37.71%5.61M | 45.10%5.27M | 49.74%4.39M | 113.93%14.87M | 71.53%4.23M | 109.84%4.07M | 142.81%3.63M | 180.13%2.93M |
Net investment income | 25.85%-568K | -45.85%3.39M | 142.61%721K | 32.51%-4.06M | -193.01%-625K | -110.30%-766K | -19.00%6.26M | -203.49%-1.69M | -527.35%-6.01M | 169.14%672K |
Gain(Loss) on financial instruments designated as cash flow hedges | -189.77%-197.4M | -37.80%82.1M | -205.66%-87.8M | -630.49%-87M | -802.59%-104.7M | 219.9M | 132M | 83.1M | 16.4M | -11.6M |
Gain(Loss) on derecognition of available-for-sale financial assets | -102.37%-7.94M | 5,169.59%334.44M | ||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -3,788.90%-188.8M | 0 | -51.44%673K | -13,495.37%-191.02M | 100.91%1.55M | 230.76%5.12M | 97.18%1.54M | 32.25%1.39M | 50.42%1.43M | 111.51%770K |
Less:Other special charges | 69.01%-1.59M | --0 | 51.44%-673K | 144.46%634K | -100.91%-1.55M | -230.76%-5.12M | -97.18%-1.54M | -32.25%-1.39M | -50.42%-1.43M | -111.51%-770K |
Less:Write off | --190.38M | --0 | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
Other non-operating income (expenses) | -82.88%-42.73M | -1,100.30%-4M | -237.12%-1.29M | -52.38%-36.57M | -4,261.90%-874K | -78.37%-23.37M | -118.04%-333K | 260.10%943K | -22.46%-24M | -99.60%21K |
Income before tax | -126.02%-160.04M | -50.52%259.63M | -66.34%54.77M | -12,710.21%-210.73M | -273.19%-263.7M | 279.60%615.1M | 655.23%524.71M | 970.42%162.7M | 97.27%-1.65M | 58.20%-70.66M |
Income tax | -3.90%211.92M | -38.77%52.08M | -49.10%47.76M | 281.63%64.9M | 91.57%47.18M | 607.80%220.52M | -10.79%85.06M | 14,293.65%93.82M | 193.71%17.01M | 154.27%24.63M |
Net income | -194.26%-371.96M | -52.79%207.55M | -89.82%7.01M | -1,377.77%-275.63M | -226.25%-310.88M | 205.61%394.59M | 331.58%439.65M | 481.98%68.88M | 55.68%-18.65M | 22.95%-95.29M |
Net income continuous operations | -194.26%-371.96M | -52.79%207.55M | -89.82%7.01M | -1,377.76%-275.63M | -226.25%-310.88M | 205.61%394.59M | 331.58%439.65M | 482.00%68.88M | 55.68%-18.65M | 22.95%-95.29M |
Noncontrolling interests | 0.15%104.34M | -23.90%32.53M | -24.37%31.23M | 90.31%25.68M | 123.83%14.91M | 241.03%104.19M | 5,919.86%42.74M | 127.75%41.3M | -0.79%13.49M | 451.96%6.66M |
Net income attributable to the company | -264.02%-476.3M | -55.90%175.02M | -187.81%-24.22M | -837.33%-301.31M | -219.56%-325.79M | 171.85%290.4M | 308.29%396.91M | 176.28%27.58M | 42.27%-32.15M | 16.28%-101.95M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -264.02%-476.3M | -55.90%175.02M | -187.81%-24.22M | -837.33%-301.31M | -219.56%-325.79M | 171.85%290.4M | 308.29%396.91M | 176.28%27.58M | 42.27%-32.15M | 16.28%-101.95M |
Gross dividend payment | ||||||||||
Basic earnings per share | -263.76%-89.35 | -55.91%32.88 | -186.71%-4.5 | -836.26%-56.55 | -219.31%-61.18 | 171.52%54.56 | 307.43%74.57 | 175.99%5.19 | 42.53%-6.04 | 16.70%-19.16 |
Diluted earnings per share | -267.76%-89.35 | -56.01%32.7993 | -187.61%-4.5395 | -836.26%-56.55 | -219.31%-61.18 | 169.81%53.26 | 307.39%74.557 | 175.86%5.1814 | 42.56%-6.04 | 16.70%-19.16 |
Dividend per share | ||||||||||
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |